212 related articles for article (PubMed ID: 35545175)
1. Optimize Local Therapy for Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer to Enhance Survival.
Chang JY; Verma V
J Natl Compr Canc Netw; 2022 May; 20(5):531-539. PubMed ID: 35545175
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline.
Iyengar P; All S; Berry MF; Boike TP; Bradfield L; Dingemans AC; Feldman J; Gomez DR; Hesketh PJ; Jabbour SK; Jeter M; Josipovic M; Lievens Y; McDonald F; Perez BA; Ricardi U; Ruffini E; De Ruysscher D; Saeed H; Schneider BJ; Senan S; Widder J; Guckenberger M
Pract Radiat Oncol; 2023; 13(5):393-412. PubMed ID: 37294262
[TBL] [Abstract][Full Text] [Related]
3. Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer.
Juan O; Popat S
Clin Lung Cancer; 2017 Nov; 18(6):595-606. PubMed ID: 28377206
[TBL] [Abstract][Full Text] [Related]
4. Local Ablative Therapies for Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer.
Jairam V; Park HS; Decker RH
Cancer J; 2020; 26(2):129-136. PubMed ID: 32205537
[TBL] [Abstract][Full Text] [Related]
5. Oligoprogression in non-small cell lung cancer: a narrative review.
Nguyen KT; Sakthivel G; Milano MT; Qiu H; Singh DP
J Thorac Dis; 2022 Dec; 14(12):4998-5011. PubMed ID: 36647502
[TBL] [Abstract][Full Text] [Related]
6. The evolving role of radiotherapy in treatment of oligometastatic NSCLC.
Bergsma DP; Salama JK; Singh DP; Chmura SJ; Milano MT
Expert Rev Anticancer Ther; 2015; 15(12):1459-71. PubMed ID: 26536370
[TBL] [Abstract][Full Text] [Related]
7. Local Ablative Therapies in Oligometastatic NSCLC: New Data and New Directions.
Lang P; Gomez DR; Palma DA
Semin Respir Crit Care Med; 2020 Jun; 41(3):369-376. PubMed ID: 32450591
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer.
Kissel M; Martel-Lafay I; Lequesne J; Faivre JC; Le Péchoux C; Stefan D; Barraux V; Loiseau C; Grellard JM; Danhier S; Lerouge D; Chouaid C; Gervais R; Thariat J
BMC Cancer; 2019 Dec; 19(1):1237. PubMed ID: 31856742
[TBL] [Abstract][Full Text] [Related]
9. American Radium Society Appropriate Use Criteria for Radiation Therapy in Oligometastatic or Oligoprogressive Non-Small Cell Lung Cancer.
Amini A; Verma V; Simone CB; Chetty IJ; Chun SG; Donington J; Edelman MJ; Higgins KA; Kestin LL; Movsas B; Rodrigues GB; Rosenzweig KE; Rybkin II; Slotman BJ; Wolf A; Chang JY
Int J Radiat Oncol Biol Phys; 2022 Feb; 112(2):361-375. PubMed ID: 34571054
[TBL] [Abstract][Full Text] [Related]
10. The role of local ablative therapy in oligometastatic non-small-cell lung cancer: hype or hope.
Bansal P; Rusthoven C; Boumber Y; Gan GN
Future Oncol; 2016 Dec; 12(23):2713-2727. PubMed ID: 27467543
[TBL] [Abstract][Full Text] [Related]
11. [Radiotherapy for oligometastatic non-small cell lung cancer patients].
Levy A; Roux C; Mercier O; Issard J; Botticella A; Barlesi F; Le Péchoux C
Cancer Radiother; 2021 Oct; 25(6-7):517-522. PubMed ID: 34175225
[TBL] [Abstract][Full Text] [Related]
12. Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with "curative" intent.
Buglione M; Jereczek-Fossa BA; Bonù ML; Franceschini D; Fodor A; Zanetti IB; Gerardi MA; Borghetti P; Tomasini D; Di Muzio NG; Oneta O; Scorsetti M; Franzese C; Romanelli P; Catalano G; Dell'Oca I; Beltramo G; Ivaldi GB; Laudati A; Magrini SM; Antognoni P;
Lung Cancer; 2020 Mar; 141():1-8. PubMed ID: 31926440
[TBL] [Abstract][Full Text] [Related]
13. Role of radiation in oligometastases and oligoprogression in metastatic non-small cell lung cancer: consensus and controversy.
Kumar A; Salama JK
Expert Rev Respir Med; 2023; 17(11):1033-1040. PubMed ID: 37962878
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic radiotherapy in oligometastatic cancer.
Kennedy TAC; Corkum MT; Louie AV
Chin Clin Oncol; 2017 Sep; 6(Suppl 2):S16. PubMed ID: 28917254
[TBL] [Abstract][Full Text] [Related]
15. [Therapeutic options for oligoprogressive non-small cell lung cancer].
Gustin P; Botticella A; Tselikas L; Mercier O; Le Péchoux C; Levy A
Rev Mal Respir; 2019 Apr; 36(4):519-526. PubMed ID: 31010758
[TBL] [Abstract][Full Text] [Related]
16. Oligometastatic non-small cell lung cancer: a narrative review of stereotactic ablative radiotherapy.
Dohopolski M; Iyengar P
Ann Palliat Med; 2021 May; 10(5):5944-5953. PubMed ID: 33691460
[TBL] [Abstract][Full Text] [Related]
17. The Management of Oligometastases in Non-small Cell Lung Cancer - is Stereotactic Ablative Radiotherapy now Standard of Care?
Ratnakumaran R; McDonald F
Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):753-760. PubMed ID: 36117126
[TBL] [Abstract][Full Text] [Related]
18. Role of Local Ablative Therapy in Patients with Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer.
Kim C; Hoang CD; Kesarwala AH; Schrump DS; Guha U; Rajan A
J Thorac Oncol; 2017 Feb; 12(2):179-193. PubMed ID: 27780780
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of oligometastatic or oligoprogression cancer].
Bourgier C; Latorzeff I; Fenoglietto P; Boisselier P; Charissoux M; Llacer C; Lemanski C; Riou O; Farcy-Jacquet MP; Azria D
Cancer Radiother; 2019 Oct; 23(6-7):482-485. PubMed ID: 31495737
[TBL] [Abstract][Full Text] [Related]
20. Oligometastatic breast cancer: where are we now and where are we headed?-a narrative review.
Kent CL; McDuff SGR; Salama JK
Ann Palliat Med; 2021 May; 10(5):5954-5968. PubMed ID: 32921069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]